The Investor Manifesto
Advertisement
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
The Investor Manifesto
No Result
View All Result
Home Investing

Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America

May 16, 2024
in Investing
Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Fungtional Labs is a leading provider of cultivation supplies and food-grade functional mushrooms in North America. The company’s vertically integrated business model provides robust differentiation over its peers. From cultivation and extraction to testing and end-product sales and distribution, the model ensures multiple revenue streams for Fungtional Labs.

Fungtional Labs’ cultivation supplies based on its proprietary all-in-one growing media include sterilized media, spawn genetics, all-in-one grow bags, pellets and masters mix. The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts.

​Revenue Streams

Some of the company’s revenue streams include selling food-grade gourmet and functional mushrooms in North America and bulk substrates, growing medias, genetics, growing equipment, which has generated significant demand among cultivators and commercial growers.

Company Highlights

Fungtional Labs is a vertically integrated business model that provides products from cultivation to end-product consumer sales and distribution. This provides an advantage over peers by eliminating intermediaries.Fungtional Labs is a supplier of cultivation and genetic products for mushroom cultivators in North America, leveraging its proprietary all-in-one growing media. The company’s products include sterilized media, spawn genetics and all-in-one grow bags.The company’s proprietary organic master mix growing media is in high demand among cultivators, providing higher yield at lower costs.The company plans to implement its business model over three phases – Phase 1 will focus on providing mycological supplies and producing functional mushroom varieties; 2) Phase 2 will focus on processing finished products, as well as focus on submitting a licensed dealer application to manufacture psilocybin-enhanced products; and 3) Phase 3 will involve B2B white labelling services, as well as, operating as a licensed dealer in the psychedelics market.The company’s mycological division, which supplies all-natural growth formulas and extraction methods, stands to benefit from sector tailwinds and a large addressable market. The global food fungi market is expected to grow to $69 billion by 2024, while the medicinal mushroom extract market is expected to reach $18 billion by 2024.The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts. The company anticipates to provide different delivery systems to very evolving psychedelic market. The psychedelic market presents a large opportunity for the company given that the market is projected to grow at a CAGR of 16.3 percent by 2027.

This Fungtional Labs profile is part of a paid investor education campaign.*

Click here to connect with Fungtional Labs to receive an Investor Presentation

This post appeared first on investingnews.com

Previous Post

PROPOSED NOMINATIONS TO STRENGTHEN WESTERN COPPER AND GOLD’s BOARD

Next Post

Prospect Ridge Resources

Next Post
Prospect Ridge Resources

Prospect Ridge Resources

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Anti-abortion provider measure in Trump’s ‘big, beautiful bill’ could spark House GOP rebellion

    Anti-abortion provider measure in Trump’s ‘big, beautiful bill’ could spark House GOP rebellion

    May 12, 2025
    4th round of US-Iran talks ends as Trump set to embark on historic Middle East tour

    4th round of US-Iran talks ends as Trump set to embark on historic Middle East tour

    May 12, 2025
    Acceleration of RAD204 Phase 1 dose escalation trial

    Acceleration of RAD204 Phase 1 dose escalation trial

    May 12, 2025
    Multiple New Multi-Commodity Targets

    Multiple New Multi-Commodity Targets

    May 12, 2025
    Disclaimer: TheInvestorManifesto.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Popular

    Group Eleven Intersects 12.0m of 2.30% Cu and 560 g/t Ag, Including 6.4m of 3.72% Cu and 838 g/t Ag, Demonstrating High-Grade Copper and Silver Potential at Ballywire
    Investing

    Group Eleven Intersects 12.0m of 2.30% Cu and 560 g/t Ag, Including 6.4m of 3.72% Cu and 838 g/t Ag, Demonstrating High-Grade Copper and Silver Potential at Ballywire

    May 8, 2025

    Read more

    Recent News

    Anti-abortion provider measure in Trump’s ‘big, beautiful bill’ could spark House GOP rebellion

    Anti-abortion provider measure in Trump’s ‘big, beautiful bill’ could spark House GOP rebellion

    May 12, 2025
    4th round of US-Iran talks ends as Trump set to embark on historic Middle East tour

    4th round of US-Iran talks ends as Trump set to embark on historic Middle East tour

    May 12, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved

    No Result
    View All Result
    • Business
    • Politics
    • Investing
    • Stocks

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved